About the company
Revolution Medicines Inc is a pioneering clinical-stage precision oncology company at the forefront of developing innovative targeted therapies. Their primary goal is to combat elusive and challenging growth and survival pathways in cancer cells. With a particular focus on the RAS and mTOR signaling pathways, Revolution Medicines aims to conquer some of the most notorious targets in the field of oncology. Among Revolution Medicines' key products is RMC-4630, a powerful inhibitor of SHP2. SHP2 is an enzyme that plays a significant role in the RAS signaling pathway, a genetic pathway that regulates cell growth and proliferation. Dysregulation of the RAS pathway is found in numerous cancers and is associated with poor prognosis. By inhibiting SHP2, RMC-4630 has shown promise in halting RAS-driven tumor growth and improving patient outcomes. The development of such targeted therapies provides hope for improving the treatment options available for patients with RAS-driven cancers. Revolution Medicines also boasts an impressive RAS(ON) portfolio, which addresses the complexities of RAS-related cancers. The RAS family of genes includes H-RAS, N-RAS, and K-RAS, and mutations in these genes are frequently found in various types of cancer. Revolution Medicines' RAS(ON) portfolio aims to develop therapies that can effectively target these mutated RAS proteins, preventing them from multiplying and driving cancer progression. By strategizing and developing innovative ways to combat RAS-related cancers, the company is actively advancing the field of precision oncology. Another significant focus of Revolution Medicines is their SOS1 program. SOS1 is a protein that plays a key role in the activation of RAS proteins. By studying and targeting SOS1, Revolution Medicines hopes to interrupt the activation of mutated RAS proteins and halt cancer growth. This program has the potential to revolutionize the treatment landscape for RAS-driven cancers, where effective therapeutic options are currently limited. Additionally, Revolution Medicines is exploring the 4EBP1/mTORC1 pathway, which regulates protein synthesis in cancer cells. The mTORC1 complex plays a critical role in tumor growth and survival. By developing inhibitors targeting this pathway, Revolution Medicines aims to disrupt the aberrant protein synthesis that enables cancer cells to thrive. This innovative approach has the potential to significantly impact the treatment of cancers driven by dysregulated mTOR signaling. Revolution Medicines' commitment to precision oncology extends beyond the development of groundbreaking therapies. The company is also deeply invested in ongoing research efforts, collaborating with academic institutions and pharmaceutical partners worldwide. Their collaborative approach enables them to leverage diverse scientific expertise to further enhance their understanding of elusive cancer targets and develop improved treatment strategies. In summary, Revolution Medicines Inc is leading the charge in precision oncology, focused on developing novel therapies to overcome the challenges posed by elusive growth and survival pathways in cancer cells. Their pipeline features groundbreaking inhibitors targeting various proteins within the RAS and mTOR signaling pathways, offering hope for patients with RAS-driven cancers. Through their innovative research and collaborative efforts, Revolution Medicines strives to transform the future of cancer treatment.
Website: https://www.revmed.com
Data updated: June 2, 2026
